The recent literature on the molecular genetics of schizophrenia is reviewed, to familiarize the reader with several important developments as well as a broad range of research efforts in a rapidly progressing field. Recent findings New genome scan projects, seen in the light of previous scans, provide support for schizophrenia candidate regions on chromosomes 1q, 2q, 5q, 6p, 6q, 8p, 10p, 13q, 15q and 22q. Linkage disequilibrium mapping studies of several of these regions have produced evidence from relatively large samples supporting the association of schizophrenia to neuregulin-1 (NRG1, 8p21-p12), dysbindin (DTNBP1, 6p22.3), proline dehydrogenase (PRODH2, 22q11.21), G72 (13q34) with weaker evidence implicating its interacting gene D-amino acid oxidase (DAAO, 12q24), and catechol-O-methyltransferase (COMT, 22q11.21). Other reports have described including the application of microarray techniques to schizophrenia postmortem tissue, candidate gene studies in diverse regions, efforts to develop quantitative phenotypes (e.g. neuroimaging and neuropsychological variables) and proposed models of schizophrenia pathogenesis. Summary Schizophrenia linkage findings are beginning to converge on a number of chromosomal regions. Linkage disequilibrium mapping studies are beginning to produce findings of great interest in some of these regions, and additional findings should be expected. Enlarged linkage and association samples, combined with rapidly evolving technologies, hold out the promise that in the next 5-10 years, the role of some specific schizophrenia susceptibility genes will be confirmed resulting in an initial understanding of the pathogenesis of schizophrenia.
Introduction
], one of which detected a gene for which evidence for genetic association was also observed [17 . . ]. It appears likely that positional cloning, microarray and other technologies will soon produce replicable findings that will begin to elucidate the pathophysiology of this severe common disease.
Progress in finding genes through positional cloning methods
Positional cloning is the primary strategy available for finding susceptibility genes for disorders with no known pathophysiology. The strategy is summarized in Table 1 .
Multiply affected families are screened with a DNA marker map of all chromosomes (genome scan). Statistical analyses consider whether ill relatives have inherited the same marker alleles, indicating the proximity of a disease susceptibility gene. For complex disorders (such as schizophrenia) that probably have multiple interacting susceptibility genes, genome scans can only locate genes within 10 000 000-30 000 000 base pair (bp) regions.
In these candidate regions, additional markers are genotyped 1-2 cM apart, which sometimes narrows the candidate region.
Linkage disequilibrium (LD) mapping is based on a different principle: most of the genome's DNA sequence variations have arisen only once or a few times. Some 'unrelated' ill individuals may have inherited from a single ancient ancestor an identical DNA segment that increases the risk of disease. Each patient's complete DNA sequence cannot yet be sequenced cost-effectively, but one can study many variations (single-nucleotide polymorphisms; SNPs) 10 000-50 000 bp (10-50 kb) apart in the candidate region in 'unrelated' cases to look for 'haplotypes' (adjacent variations on the same chromosome) that are more common in ill individuals. It is believed that some (not all) susceptibility variants underlying common complex disorders can be identified in this way with larger samples, improved SNP maps and evolving molecular methods.
Functional studies can then be initiated to determine the gene's function, interactions and possible relationship to the disease.
Generally, two genome scan strategies have been employed. One is to study small samples of families with as many ill relatives as possible, in the hope that one or a few genes are conferring most of the risk of disease [18 . . ,19
. . ]. The other is to collect many families with at least an affected sibling pair (ASP), assuming that multiple interacting genes each confer a small proportion of risk [20] , so that hundreds to thousands of families will be needed [21] . The complexities of this debate are beyond the scope of this paper. Existing data about familial patterns of schizophrenia tend to support the second view [20] . Small samples tend to exaggerate the genetic effects of some loci while missing others entirely [22, 23] . However, some of the better-supported linkage findings in schizophrenia were initially detected in small samples [24, 25] .
New genome scans
Eight new scans and one partial scan were published this past year. Regarding the interpretation of scan results, 'genome-wide significance' usually refers to a result that is expected to occur by chance once in 20 scans, and 'suggestive significance' refers to a result that would occur once per scan on average [26] . However, for complex disorders, statistically significant linkage is not reliably observed at feasible sample sizes, and the pattern of results across studies may prove to be more important. In this discussion, 'narrow' diagnoses refer generally to schizophrenia and schizoaffective disorder, and 'broad' or 'spectrum' diagnoses refer to schizophrenia-related psychoses and personality disorders.
Straub et al. [1
. . ] published scan results for 270 Irish pedigrees. They previously reported evidence for linkage on chromosome 6p21-24, which approached genome-wide significance depending on how one corrects for multiple tests [27] , and suggestive evidence on 5q21-31 [28] , 8p22-21 [29] and 10p15-p11 [30] . Results suggested at least two susceptibility loci on chromosome 6p, both of which have been supported by other studies (see below), but peaks this close together are difficult to prove with current methods. This relatively large sample was drawn from one ethnic population, which might improve the power to detect linkage [31] . But the scan was completed some years ago using three different, sparse (20-30 cM) maps in subsamples of 90 families. A range of diagnostic and genetic models were analysed to explore the data fully, but this also makes the findings more difficult to interpret.
. . ] published two scans. The largest schizophrenia scan to date was of 294 families (333 independent ASPs). Two suggestive findings were . It is likely that that some or perhaps many of these candidate regions contain schizophrenia susceptibility loci, each contributing to a small increase in population-wide risk (although some loci could have larger effects in individual families).
Candidate genes in positional candidate regions
For the first time, LD mapping studies of positional candidate regions have implicated specific genes in schizophrenia susceptibility. Previously, no strong and replicable candidate genes had emerged from studies of genes involved in antipsychotic drug mechanisms (e.g. dopamine receptors) or in central nervous system processes that could be hypothetically related to schizophrenia. In the absence of evidence for linkage in a region, the prior probability for the association of a gene is so low that statistical proof becomes extremely difficult [38] . These new reports ( ]. LD mapping studies in cases and controls suggested the association of individual SNPs and SNP haplotypes in NRG1 (neuregulin-1, 8p21-p12). The 'core' haplotype was observed in 15.4% of 478 affected cases and 7.5% of 394 controls, with P = 0.000087 for cases not known to be related. NRG1 is a glycoprotein with a variety of isoforms that bind to the ErbB family of tyrosine kinase transmembrane receptors. NRG1 and ErbB4 heterozygous mutant mice demonstrated hyperactivity that was reduced by very low doses of clozapine, slightly deficient pre-pulse inhibition, and a small reduction in functional N-methyl-D-aspartate (NMDA) receptors. Note that NRG1 lies 9-25 cM towards the centromere from previously reported 8p linkage peaks, and it is possible that another gene in that region, rather than a variation in NRG1, will prove to explain those findings. 
,19
. . ,27]. Dysbindin binds to dystrobrevin, part of the protein complex involved in the pathogenesis of muscular dystrophy. These proteins have diverse functions related to neurotransmitter signal transduction. Evidence supporting this association has recently been reported in two German samples [39] .
PRODH2
Individuals with velo-cardio facial syndrome (VCFS) are at a substantially increased risk of schizophrenia [40] [41] [42] , so that the identification of the relevant genes in the 22q11 microdeletion region is an important task. Liu et al. [12 . . ] reported the association of schizophrenia to SNPs in PRODH2 (proline dehydrogenase, 22q11.21), particularly in childhood cases and in adults with age at onset below the age of 18 years. Evidence for association was modest, but was observed in three separate small samples. Proline dehydrogenase is a mitochrondrial enzyme involved in transferring redox potential across the mitochondrial membrane. . ] proposed that COMT sequence variation modifies cognition through effects on dopaminergic transmission in prefrontal cortex.
G72 and DAAO
Such reports usher in a new era in schizophrenia genetics. One might expect more such reports to appear over the next 3-5 years, with increasingly large samples supporting the association of schizophrenia with plausible candidate genes in linkage candidate regions, or genes identified by large-scale expression studies. Initial reports may be difficult to interpret: many tests must be performed on SNPs and haplotypes, and there is no definitive threshold for a significant finding. Data mining techniques are evolving in this field, and replication is likely to be the cornerstone of data interpretation. The author would predict that, despite these difficulties, the pattern of replication studies and physiological findings will ultimately become clear and convincing for at least some of the new candidate genes. Through this process, the first real clues to the pathophysiology of schizophrenia are likely to emerge.
Other studies of candidate regions and genes
Other noteworthy reports include applications of microarray technology and studies of candidate genes in pharmacologically-relevant neurotransmitter systems and in positional candidate regions.
Probing the genome with microarrays
Several studies demonstrated the emerging potential of microarray methods to probe the genome or proteome for candidate pathways. . . ] probed 18 000 messenger RNAs in case and control brains and demonstrated significant differences in the expression for a number of genes. A further example is discussed for chromosome 22q (below).
Genes related to dopaminergic neurotransmission
Schizophrenia has not been convincingly associated with polymorphisms in genes related to dopaminergic function, although meta-analyses have suggested a small but significant association for homozygosity at a polymorphism in DRD3 (3q13.3) [50] . There are two recent reports of slightly positive evidence for an association at DRD2 (11q22-q23) [ 
,19
. . ], no association was observed in recent reports on class I alleles in Japanese cases and controls [86 . ], in class II DRB1, DQA1, DQB1 and DPB1 alleles in Han Chinese trios [87 . ], or in DQB1, DRB1, DQA1, or HLA-A alleles or haplotypes in primarily European sib-pair families and trios [85 . ]. Reports on DTNBP1 and on 6q linkage have been discussed above.
Chromosome 8p
No association with schizophrenia was observed for markers in three plausible candidate genes (PNOC, CHRNA2 and NAT1) [88 . ] in the 8p21-22 linkage region discussed above.
Chromosome 15q
Freedman and colleagues [89] demonstrated the highly significant linkage of chromosome 15q13-q14 to deficient inhibition of the P50 auditory evoked potential (pre-pulse inhibition) in schizophrenia probands and their affected and unaffected relatives, and showed that the alpha-7 nicotinic receptor gene (CHRNA7) was involved in this deficit in animals and was a plausible candidate gene for schizophrenia [90] [91] [92] . However, evidence for linkage to schizophrenia in this region had been modest. Now, a re-analysis of the NIMH Schizophrenia Genetics Initiative genome scan using a dominant parametric lod score analysis produced significant evidence for linkage on 15q13-q14 [ ] carried out a cDNA microarray-based gene expression analysis of schizophrenia and control brains from two collections, and in both they found an increased expression of APOL1, APOL2 and APOL4 (apolipoproteins 1, 2 and 4, all in 22q12 outside the VCFS deletion region). These findings suggest a possible pathway in schizophrenia pathogenesis.
Other candidate genes
A role in schizophrenia has been hypothesized for cholecystokinin (CCK, (3p22-p21.3 Additional negative association studies of candidate genes published during the review period will not be discussed in detail here [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] .
Progress in identifying quantitative traits for genetic studies
There were several reports about schizophrenia-related quantitative traits that showed promise as phenotypes for genetic studies.
Neuropsychological measures
In 264 cases and relatives from a geographical isolate in Finland, measures of working memory showed strong heritability, possibly because of a small number of contributing loci [137 . ]. Measures of memory and IQ declined before the onset of psychosis in high-risk individuals in the Edinburgh high-risk project [138] . However, in the same project, attentional dysfunction did not differentiate the relatives of schizophrenic versus control subjects [139 . ].
Neuro-imaging measures
In a creative analysis from the Edinburgh project, a reduced volume of the amygdalohippocampal complex was observed in 'obligate carriers' (well individuals with a schizophrenic sibling and offspring) [140 . ]. In a study of monozygotic and dizygotic twins discordant for schizophrenia and control twins, an upward bowing of the corpus callosum was also suggested to be a marker of vulnerability [141 . ].
Neurological signs
Neurological signs were increased in the relatives of schizophrenia patients, but the low relative risk versus controls suggested that they might be poor genetic markers [142 . ]. A pattern of dysmorphic features was found to differentiate a subgroup of 18 schizophrenia cases from other clusters in a sample of 123 clinical schizophrenia cases and 36 cases referred for possible VCFS [143] .
Clinical dimensions
Cardno et al. [144 . ] showed that 'first-rank' symptoms (such as delusions of being controlled or hearing voices conversing) were heritable in the Maudsley twin series, but less so than the category of schizophrenia. They also reported that genetic liability to schizophrenic, manic and depressive symptoms appeared to overlap substantially when rated non-hierarchically [145 . ]. Kendler [146 . ], in a commentary on the latter study, suggested that the data are better interpreted as showing that manic and depressive syndromes are somewhat heritable in individuals with schizophrenia, because no genetic overlap was shown between individuals with primary diagnoses of schizophrenic and mood disorders.
Models for genetic studies of schizophrenia
Several intriguing models have been proposed for conceptualizing genetic factors in schizophrenia.
Advancing paternal age and de-novo mutations
A re-analysis of data from a birth cohort study demonstrated that advancing paternal age slightly but significantly increased the risk of schizophrenia, after adjusting for possible confounding factors such as maternal age [ 
Conclusion
The pace of discovery is accelerating in the field of schizophrenia genetics. The most striking developments in the past year have included the apparent convergence of new and older linkage data on a number of chromosomal regions, and the first reports of LD mapping data supporting specific candidate genes in linkage candidate regions. NRG1, DTNBP1, G72/DAAO and COMT were all studied in 400 or more cases, more than in most previous candidate gene studies. However, inadequate power remains a problem in both linkage and LD mapping studies: ideally, it would be preferable to have several linkage samples of 500-1000 pedigrees and several association samples of 1000-3000 cases and controls or proband-parent trios. Association data from very small samples remain difficult to interpret.
The next few years are likely to see the completion of the haplotype structure map ('HapMap') and a rapid decline in the cost of very high-throughput SNP genotyping. The HapMap project will identify a minimal set of approximately 100 000-500 000 SNPs, which define local 10-50 000 bp blocks of LD, i.e. the old, common variation in the human genome [155] [156] [157] [158] . The hypothesis to be tested is that at least some of the predisposing DNA sequence variations for common complex disorders may be in LD with these blocks. However, there may be too many different predisposing variations in different populations, with little correlation between the observable phenotype and underlying genotype [159] . It is likely that cost-efficient methods will be developed to detect all sequence variations in candidate regions [160] , so that one might also detect an excess of rare variations in cases. Diverse microarray strategies offer additional tools to identify functionally relevant genes, proteins and pathways, and although these will not always be causal [159] , they are likely to yield insights for treatment and ultimately for better causal hypotheses.
An article by a social scientist suggested some concluding reflections: Conrad [161 . ] critiqued the widespread media endorsement of 'genetic optimism', 'which emphasizes the inevitability of discovering genes and the good outcomes of those discoveries, while negative or retracted findings receive no attention. Scientific colleagues in genetics and other fields are prone to similar distortions' (p. 225). However, optimism is far from the dominant theme in the scientific community. Rather, we see an unfortunate oscillation: scientists as well as the media tend to make exaggeratedly positive claims, and then the 'negative and retracted findings' have led to profound skepticism. What is needed is a balanced and steady approach for the long haul. In this author's view, the cornerstone of progress should be the logic of positional cloning: by utilizing data from linkage studies (and perhaps in the future, microarray studies) in a critical way -cognizant of methodological shortcomings and realistic about the strength of results and the power of samples -it should be possible to move from candidate regions to candidate genes to the beginnings of an understanding of schizophrenia pathophysiology in the next decade.
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